Floatz logo

Xaliplatin

Metastasis From Malignant Tumor Of Colon

Fudan UniversitySmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Metastasis From Malignant Tumor Of Colon cohort.

Asset / SponsorPhaseRating
Fruquintinib
Peking University
Phase 3BBB
Dexasone
Fudan University
Phase 3BB
Irinotecan
Jun Huang
Phase 3BB
Capecitabine
Jun Huang
Phase 3BB
Cetuximab
Shanghai 6th People's Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Xaliplatin is also rated in:

exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
rectal cancerActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →